L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.

  title={L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.},
  author={Evguenia S. Svarovskaia and Edward J. Gane and Hadas Dvory-Sobol and Ross Martin and Brian P Doehle and Charlotte Hedskog and I M for the New Paradigm of HCV Therapy Meeting Part Jacobson and David R. Nelson and Eric J. Lawitz and Diana M. Brainard and John McHutchison and Michael D. Miller and Hongmei Mo},
  journal={The Journal of infectious diseases},
  volume={213 8},
BACKGROUND Sofosbuvir (SOF) exhibits a high barrier to resistance, with no S282T NS5B substitution or phenotypic resistance detected in phase 3 registration studies. METHODS Here, emergence of the NS5B variants L159F and V321A and possible association with resistance was evaluated in 8 studies of SOF (NEUTRINO, FISSION, POSITRON, FUSION, VALENCE, PHOTON-1, PHOTON-2, and P7977-2025) and 5 studies of combination ledipasvir (LDV) and SOF (LDV/SOF; LONESTAR, ELECTRON [LDV/SOF arms], ION1, ION2… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
22 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 22 extracted citations

Similar Papers

Loading similar papers…